Cervical Cancer Fight Lands at University of Alabama-Birmingham
May 18, 2009
A new, less expensive vaccine against human papillomavirus (HPV) will be tested at the University of Alabama-Birmingham (UAB) beginning late this year or early next year.
Animal studies of the candidate vaccine show it produces an immune response against all 15 HPV types known to cause cervical cancer, said Roden. "The animal data is very supportive that it will work. My biggest concern is how long the protection will last," he said, adding that the clinical trials will provide that information.
UAB will be the sole testing site for the candidate vaccine, said Dr. Warner H. Huh, a gynecologic oncologist at the school who worked on the Gardasil vaccine trials and will head the new clinical trials. UAB serves mainly minority, rural, and poor communities -- groups at higher risk for cervical cancer. In addition, the region has high rates of smoking, a risk factor for cervical cancer.
The new vaccine's safety trial will involve about 50 volunteers. A second trial will concentrate on dosing. If warranted, a third will likely expand in scope to involve many more medical centers and participants.
03.30.2009; Dave Parks
This article was provided by U.S. Centers for Disease Control and Prevention. It is a part of the publication CDC HIV/Hepatitis/STD/TB Prevention News Update. Visit the CDC's website to find out more about their activities, publications and services.